A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI-1027 in Patients With Low HDL-C and Either Normal or Elevated Triglycerides
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Gemcabene (Primary)
- Indications Hypercholesterolaemia; Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Gemphire Therapeutics; NeuroBo Pharmaceuticals
- 31 Oct 2016 Results published in Gemphire Therapeutics media release.
- 15 Sep 2016 New trial record